Journal of Vascular Surgery
Volume 50, Issue 6 , Pages 1359-1368.e1 , December 2009

Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: The V-HEALTH study

Part of the work described in this manuscript was presented in poster form at the American Society of Nephrology 2008 Annual Meeting in Philadelphia, Penn and as an oral presentation at the Thirty-fifth Annual VEITHsymposium™ in 2008.

  • Michael S. Conte, MD

      Affiliations

    • Department of Vascular and Endovascular Surgery, University of California, San Francisco, Calif
    • Corresponding Author InformationReprint requests: Michael S. Conte, University of California, San Francisco Division of Vascular and Endovascular Surgery, 400 Parnassus Avenue, Suite A581, San Francisco, CA 94143-0222
    • ,
  • Helen M. Nugent, PhD

      Affiliations

    • Pervasis Therapeutics, Cambridge, Mass
    • ,
  • Peter Gaccione, MA

      Affiliations

    • Pervasis Therapeutics, Cambridge, Mass
    • ,
  • Indira Guleria, MD

      Affiliations

    • Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital, Harvard Medical School, Boston, Mass
    • ,
  • Prabir Roy-Chaudhury, MD, PhD

      Affiliations

    • Cincinnati Dialysis Program, University of Cincinnati, Cincinnati, Ohio
    • ,
  • Jeffrey H. Lawson, MD, PhD

      Affiliations

    • Department of Surgery, Duke University Medical Center, Durham, NC

Received 3 May 2009 ,Accepted 25 July 2009.

References 

  1. US Renal Data System. 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2008;
  2. Feldman H, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol. 1996;7:523–535
  3. Beathard GA. The treatment of vascular access graft dysfunction: a nephrologist's view and experience. Adv Renal Replace Ther. 1994;1:131–147
  4. Roy-Chaudhury P, Spergel LM, Besarab A, Asif A, Ravani P. Biology of arteriovenous fistula failure. J Nephrol. 2007;20:150–163
  5. Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA. 2008;299:2164–2171
  6. Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol. 2006;17:1112–1127
  7. Asif A, Gadalean FN, Merrill D, Cherla G, Cipleu CD, Epstein DL, et al. Inflow stenosis in arteriovenous fistulas and grafts: a multicenter, prospective study. Kidney Int. 2005;67:1986–1992
  8. Turmel-Rodrigues L, Pengloan J, Baudin S, Testou D, Abaza M, Dahdah G, et al. Treatment of stenosis and thrombosis in hemodialysis fistulas and grafts by interventional radiology. Nephrol Dial Transplant. 2000;15:2029–2036
  9. Tordoir JH, Rooyens P, Dammers R, van der Sande FM, de Haan M, Yo TI. Prospective evaluation of failure modes in autogenous radiocephalic wrist access for hemodialysis. Nephrol Dial Transplant. 2003;18:378–383
  10. Forsten KE, Courant NA, Nugent MA. Endothelial proteoglycans inhibit bFGF binding and mitogenesis. J Cell Physiol. 1997;172:209–220
  11. Dinbergs ID, Brown L, Edelman ER. Cellular response to transforming growth factor-beta1 and basic fibroblast growth factor depends on release kinetics and extracellular matrix interactions. J Biol Chem. 1996;271:29822–29829
  12. Kojima T, Leone CW, Marchildon GA, Marcum JA, Rosenberg RD. Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat microvascular endothelial cells. J Biol Chem. 1992;267:4859–4869
  13. Borrelli V, di Marzo L, Sapienza P, Colasanti M, Moroni E, Cavallaro A. Role of platelet-derived growth factor and transforming growth factor beta1 the in the regulation of metalloproteinase expressions. Surgery. 2006;140:454–463
  14. Roy-Chaudhury P, Kelly BS, Narayana A, Desai P, Melhem M, Munda R, et al. Hemodialysis vascular access dysfunction from basic biology to clinical intervention. Adv Renal Replace Ther. 2002;9:74–84
  15. Woods JD, Turenne MN, Strawderman RL, Young EW, Hirth RA, Port FK, et al. Vascular access survival among incident hemodialysis patients in the United States. Am J Kidney Dis. 1997;30:50–57
  16. Dixon BS, Novak L, Fangman J. Hemodialysis vascular access survival: upper-arm native arteriovenous fistula. Am J Kidney Dis. 2002;39:92–101
  17. Zilla P, Deutsch M, Meinhart J, Puschmann R, Eberl T, Minar E, et al. Clinical in vitro endothelialization of femoropopliteal bypass grafts: an actuarial follow-up over three years. J Vasc Surg. 1994;19:540–548
  18. Wilson JM, Birinyi LK, Salomon RN, Libby P, Callow AD, Mulligan RC. Implantation of vascular grafts lined with genetically modified endothelial cells. Science. 1989;244:1344–1346
  19. Nathan A, Nugent MA, Edelman ER. Tissue engineered perivascular endothelial cell implants regulate vascular injury. Proc Natl Acad Sci USA. 1995;92:8130–8134
  20. Nugent HM, Rogers C, Edelman ER. Endothelial implants inhibit intimal hyperplasia after porcine angioplasty. Circ Res. 1999;84:384–391
  21. Nugent HM, Sjin RT, White D, Milton LG, Manson RJ, Lawson JH, et al. Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts. J Vasc Surg. 2007;46:548–556
  22. Hughes D, Fu AA, Puggioni A, Glockner JF, Anwer B, McGuire AM, et al. Adventitial transplantation of blood outgrowth endothelial cells in porcine hemodialysis grafts alleviates hypoxia and decreases neointimal proliferation through a matrix metalloproteinase-9-mediated pathway–a pilot study. Nephrol Dial Transplant. 2009;24:85–96
  23. Nugent HM, Groothuis A, Seifert P, Guerraro JL, Nedelman M, Mohanakumar T, et al. Perivascular endothelial implants inhibit intimal hyperplasia in a model of arteriovenous fistulae: a safety and efficacy study in the pig. J Vasc Res. 2002;39:524–533
  24. US Food and Drug Administration. Points to Consider in the Characterization of Cell Lines Used to Produce Biologics. 1993;
  25. US Food and Drug Administration. Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues and Cellular and Tissue-based Products (HCT/Ps). 2007;
  26. Sidawy AN, Gray R, Besarab A, Henry M, Ascher E, Silva M, et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg. 2002;35:603–610
  27. Gibson KD, Gillen DL, Caps MT, Kohler TR, Sherrard DJ, Stehman-Breen CO. Vascular access survival and incidence of revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study. J Vasc Surg. 2001;34:694–700
  28. Nugent MA, Nugent HM, Iozzo RV, Sanchack K, Edelman ER. Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc Natl Acad Sci USA. 2000;97:6722–6727
  29. Nugent HM, Edelman ER. Endothelial implants provide long-term control of vascular repair in a porcine model of arterial injury. J Surg Res. 2001;99:228–234
  30. Brevetti G, Schiano V, Chiariello M. Endothelial dysfunction: a key to the pathophysiology and natural history of peripheral arterial disease?. Atherosclerosis. 2008;197:1–11
  31. Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007;3:46–56
  32. Mannarino E, Pirro M. Endothelial injury and repair: a novel theory for atherosclerosis. Angiology. 2008;59:69S–72S
  33. Zimering MB, Pan Z. Auto-antibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. J Clin Endocrin Metab. 2009;94:2171–2177
  34. Chhaya SU, Vazifdar GN, Rajadhyaksha SB. Panel reactive antibodies in patients with neoplasia and hematological disorders. Int J Hum Genet. 2004;4:147–149
  35. MacPherson BR, Hammond PB, Maniscalco CA. Alloimmunization to public HLA antigens in multi-transfused platelet recipients. Ann Clin Lab Sci. 1986;16:38–44
  36. Taaning E, Skibsted L. The frequency of platelet alloantibodies in pregnant women and the occurrence and management of neonatal alloimmune thrombocytopenic purpura. Obstet Gynecol Surv. 1990;45:521–525
  37. US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. 2007 OPTN/SRTR Annual Report: Transplant Data 1997-2006. Bethesda, MD: United States Department of Health and Human Services; 2007;
  38. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant. 2004;4:438–443
  39. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of the anti-class I antibody response. I (Clinical and pathologic features of anti-class I-mediated rejection). Transplantation. 1990;49:85–91
  40. Vo AA, Toyoda M, Peng A, Bunnapradist S, Lukovsky M, Jordan SC. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant. 2006;6:2384–2390
  41. Hayashi R, Huang E, Nissenson AR. Vascular access for hemodialysis. Nature Clin Pract. 2006;2:504–513
  42. Rotmans JI, Pasterkamp G, Verhagen HJ, Pattynama PM, Blankestijn PJ, Stroes ES. Hemodialysis access graft failure: time to revisit an unmet clinical need?. J Nephrol. 2005;18:9–20

 This study was supported by Pervasis Therapeutics.

 Competition of interest: Dr Nugent is a cofounder and has company ownership in Pervasis Therapeutics. Drs Conte, Lawson, and Roy-Chaudhury are on Pervasis' advisory board and have been paid honorariums for corporate speaking and speakers' bureau participation. Mr Gaccione has been paid consultant fees by Pervasis Therapeutics.

 Additional material for this article may be found online at www.jvascsurg.org.

 The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a competition of interest.

PII: S0741-5214(09)01579-1

doi: 10.1016/j.jvs.2009.07.108

Journal of Vascular Surgery
Volume 50, Issue 6 , Pages 1359-1368.e1 , December 2009

Article Tools

* Image Usage & Resolution